Meiji Holdings Reports Steady Growth in FY2025

Meiji Holdings Co ( (MEJHF) ) has released its Q4 earnings. Here is a breakdown of the information Meiji Holdings Co presented to its investors.

Meiji Holdings Co., Ltd., a prominent player in the food and pharmaceutical sectors, is known for its diverse product offerings ranging from dairy and confectionery to pharmaceuticals and vaccines. The company recently released its earnings report for the fiscal year ending March 31, 2025, showcasing a steady financial performance amidst challenging economic conditions.

For the fiscal year 2025, Meiji Holdings reported net sales of JPY 1,154.074 billion, marking a 4.4% increase from the previous year. Operating profit saw a modest rise of 0.5% to JPY 84.702 billion, while ordinary profit increased by 7.9% to JPY 82.013 billion. The profit attributable to owners of the parent was JPY 50.800 billion, reflecting a slight increase of 0.2%. The company also highlighted a significant increase in its chocolate business sales and a notable rise in operating profit within its dairy segment.

The pharmaceutical segment also experienced growth, with net sales increasing by 11.4% to JPY 229.6 billion and operating profit rising by 8.9% to JPY 24.7 billion. This growth was driven by strong sales in domestic pharmaceuticals and an increase in influenza vaccine shipments. However, the overseas pharmaceuticals business faced challenges due to increased R&D expenses.

Looking ahead, Meiji Holdings remains committed to its 2026 Medium-Term Business Plan, aiming for sustainable growth by balancing economic and social value. The company plans to focus on expanding its high-value product lines and strengthening its presence in international markets, particularly in the U.S. and Asia. Meiji Holdings anticipates continued growth in both its food and pharmaceutical segments, with projected increases in net sales and operating profit for the fiscal year ending March 31, 2026.